| BUSINESS STRATEGY |
is twofold: grow larger in the company's core contract chemistry business by adding more projects for more companies, and complement this effort with proprietary technology that customers are interested in and willing to pay for. Co. spent $5 million last year on an internal research effort designed to identify potential drug leads of interest to customers. "We're not trying to change our business model or become a biotech company," "but we have 350 scientists performing cutting-edge research and development day in and day out. We can leverage this to get a little more upside that increases shareholder value." |
| CORP. INFORMATION |
Along the way, the company raised $56 million in a February 1999 initial public offering (IPO) and $127 million more through a secondary offering in October 2000. Today, the stock market values Co. at about $720 million. |
| SALES VALUE |
Its contract chemistry research revenues increased from $8.2 million in 1997 to $56.8 million last year. In 2001 alone, they grew 52%. |
| UPDATE | 06.02 |
| COMPANY | This data is not available for free |
| CONTACT | This data is not available for free |
| CORP. HISTORIC |
The 10-year-old firm is held up as proof that a large and growing company can be built by hardworking chemists who successfully help pharmaceutical industry customers accelerate the drug development process. |
| LITERATURE REF. | This data is not available for free |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |